ROSETTA GENOMICS LTD | 2,995 Euro | -0,003 -0,10 % | |
| WKN: A0MMDG ISIN: IL0011026494 Ticker-Symbol: RQ1 | Berlin | 23.05.13 | 08:08 Uhr |
Branche BiotechnologieAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten
Sprache: | Leser | Medien | |
|---|---|---|---|---|
| 22.05. | Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference | 19 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, May 22, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Kenneth... Mehr lesen zu: Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference | ||||
| 20.05. | BRIEF-Rosetta Genomics up 11.8 percent in premarket trade | - | Reuters.com | |
| 20.05. | Rosetta Genomics Wins Credentialing Deal with Prime Health Services for miRview mets2 | - | Benzinga.com | |
| 20.05. | Rosetta Genomics (ROSG) Higher After Credentialing Agreement w/Prime Health | - | StreetInsider.com | |
| 20.05. | Rosetta Genomics Announces Credentialing Agreement with Prime Health Services for miRview mets2 | 21 | PR Newswire | |
| PHILADELPHIAand REHOVOT, Israel, May 20, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics... Mehr lesen zu: Rosetta Genomics Announces Credentialing Agreement with Prime Health Services for miRview mets2 | ||||
| 10.05. | Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories | 31 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, May 10, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of $625... Mehr lesen zu: Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories | ||||
| 07.05. | Rosetta Genomics microRNA-based Diagnostic Assays to be Showcased in an Industry Expert Theater Presentation at ASCO's 2013 Annual Meeting | 36 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, May 7, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces... Mehr lesen zu: Rosetta Genomics microRNA-based Diagnostic Assays to be Showcased in an Industry Expert Theater Presentation at ASCO's 2013 Annual Meeting | ||||
| 18.04. | Rosetta Genomics (ROSG) Enters Settlement with Sanra Labs | 2 | StreetInsider.com | |
| 18.04. | Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories | 30 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, April 18, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that... Mehr lesen zu: Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories | ||||
| 09.04. | Shares of Rosetta Genomics Rank the Highest in Terms of Enterprise Value to Sales Ratio in the Biotechnology Industry | 2 | SmarTrend | |
| 02.04. | Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013 | 30 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters... Mehr lesen zu: Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013 | ||||
| 01.04. | Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology | 31 | PR Newswire | |
| PHILADELPHIAand REHOVOT, Israel, April 1, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics... Mehr lesen zu: Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology | ||||
| 25.03. | Rosetta Genomics To Host Business Update Conference Call on April 10, 2013 | 25 | PR Newswire | |
| PHILADELPHIA,and REHOVOT, Israel, March 25, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics... Mehr lesen zu: Rosetta Genomics To Host Business Update Conference Call on April 10, 2013 | ||||
| 20.03. | Rosetta Genomics' CEO Presents at 25th Annual ROTH Conference - Transcript | 2 | Seeking Alpha | |
| 18.03. | Rosetta Genomics Receives 25th U.S. Patent Allowance | 40 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, March 18, 2013 /PRNewswire/ --Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of... Mehr lesen zu: Rosetta Genomics Receives 25th U.S. Patent Allowance | ||||
| 12.03. | Rosetta Genomics to Present at the 25th Annual Roth Conference | 47 | PR Newswire | |
| PHILADELPHIA and REHOVOT, Israel, March 12, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that... Mehr lesen zu: Rosetta Genomics to Present at the 25th Annual Roth Conference | ||||
| 04.03. | Rosetta Genomics sues spin-off over Monsanto sale | 9 | Globes | |
| 20.02. | Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success / RDInvesting Provides Stocks Research on ImmunoCellular Therapeutics and Rosetta Genomics | 65 | Marketwired | |
| NEW YORK, NY -- (Marketwire) -- 02/20/13 -- A sharp increase in drug approvals and mergers and acquisitions combined to create a bull market for the Biotechnology Industry in 2012. The iShares NASDAQ... Mehr lesen zu: Sharp Increase in FDA Drug Approvals a Major Factor in Biotech Industry's Success / RDInvesting Provides Stocks Research on ImmunoCellular Therapeutics and Rosetta Genomics | ||||
| 14.02. | Rosetta Genomics Wins Two Key US Patent Allowances | 1 | Benzinga.com | |
| 14.02. | Rosetta Genomics (ROSG) Receives Two U.S. Patents for microRNAs, miRNAs | 2 | StreetInsider.com | |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten |
|---|---|---|---|
| EXELIXIS | 3,532 | -0,06 % | Exelixis: AGM decisions |
| MARINA BIOTECH | 0,308 | -5,52 % | Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34 / Novel SMARTICLES(R) Technology Used to Deliver First-Ever microRNA Oncology Compound in Clinical Development |
| AETERNA ZENTARIS | 1,54 | -1,03 % | Aeterna Zentaris: Posters to be Presented on Phase 1 and Phase 2 Trials with AEZS-108 in Prostate and Breast Cancer at Upcoming ASCO Meeting |
| AGENNIX | 0,096 | -16,52 % | Agennix AG gibt Liquidation bekannt |
| GERON | 0,854 | +0,47 % | Geron Corporation - Shareholder/Analyst Call |
